| Literature DB >> 33255944 |
Anna V Vologzhanina1, Ivan E Ushakov1, Alexander A Korlyukov1,2.
Abstract
Imatinib, one of the most used therapeutic agents to treat leukemia, is an inhibitor that specifically blocks the activity of tyrosine kinases. The molecule of imatinib is flexible and contains several functional groups able to take part in H-bonding and hydrophobic interactions. Analysis of molecular conformations for this drug was carried out using density functional theory calculations of rotation potentials along single bonds and by analyzing crystal structures of imatinib-containing compounds taken from the Cambridge Structural Database and the Protein Data Bank. Rotation along the N-C bond in the region of the amide group was found to be the reason for two relatively stable molecular conformations, an extended and a folded one. The role of various types of intermolecular interactions in stabilization of the particular molecular conformation was studied in terms of (i) the likelihood of H-bond formation, and (ii) their contribution to the Voronoi molecular surface. It is shown that experimentally observed hydrogen bonds are in accord with the likelihood of their formation. The number of H-bonds in ligand-receptor complexes surpasses that in imatinib salts due to the large number of donors and acceptors of H-bonding within the binding pocket of tyrosine kinases. Contribution of hydrophilic intermolecular interactions to the Voronoi molecular surface is similar for both conformations, while π...π stacking is more typical for the folded conformation of imatinib.Entities:
Keywords: API; DFT calculations; likelihood of H-bond formation; molecular Voronoi polyhedron
Mesh:
Substances:
Year: 2020 PMID: 33255944 PMCID: PMC7731260 DOI: 10.3390/ijms21238970
Source DB: PubMed Journal: Int J Mol Sci ISSN: 1422-0067 Impact factor: 5.923
Scheme 1Schematic representation of imatinib in neutral (Ima) and protonated (HIma+, H2Ima2+) forms. Letters A–E indicate rings, and Q1–Q8 denote torsion angles about corresponding single bonds.
Figure 1Conformations of imatinib in studied compounds. Four superimposed atoms belong to the amide CPhC (O)N fragment. Compounds with CSD codes DUNTIQ (red, [30]), XAVTOF (orange, [31]), XAVTOF02 (yellow, [31]), XEJLUW (light green, [32]), and PDB codes 1IEP (green, [33]), 1OPJ (purple, [9]), 1T46 (violet, [34]), 1XBB (light grey, [35]), 2HYY (light blue, [36]), 2OIQ (cyan, [37]), 3FW1 (blue, [29]), 3GVU (sienna, [38]), 3HEC (peach pink, [39]), 3K5V (light emerald, [40]), 3MS9 (lilac, [41]), 3MSS (teal, [41]), 3OEZ (brown, [42]), 3PYY (light brown, [43]), 4CSV (magenta, [28]), 6HD4 (grey [44]), 6JOL (sea-green, [45]), 6NPE (orange-brown, [46]) are depicted.
Figure 2Modules of Q1–Q8 torsion angles of imatinib in (blue) extended and (red) folded conformations in 43 molecules found in 29 crystals.
The most valuable torsion angles for Q1–Q8 rotation and their potentials.
| Name of Dihedral Angle | Ima | HIma+ | ||
|---|---|---|---|---|
| Angle (degree) | Rotation Potential (kcal/mol) | Angle (degree) | Rotation Potential (kcal/mol) | |
| Q1 | −17.99 | 4.84 | −17.99 | 4.95 |
| Q2 | 13.78 | 15.29 | −2.22 | 16.61 |
| Q3 | −0.63 | 10.96 | 0.36 | 11.32 |
| Q4 | 177.18 | 5.53 | 176.18 | 4.88 |
| Q5 | 178.85 | 17.43 | 178.85 | 18.82 |
| Q6 | 25.54 | 4.22 | 153.54 | 5.36 |
| Q7 | 140.00 | 5.89 | 56.00 | 9.10 |
| Q8 | −165.11 | 7.00 | −170.11 | 6.05 |
Propensities of H-bonding in Ima and HIma+ molecules.
| Donor | Acceptor | Ima | HIma+ | Observed in CSD | Observed in PDB 1 | Observed in PDB 2 |
|---|---|---|---|---|---|---|
| Amine R2NH | N (pyridine) | 0.5 | 0.39 | |||
| O=C | 0.41 | 0.34 | Yes | |||
| N (pyrimidine) | 0.21 | 0.15–0.22 | ||||
| N (piperidyl) | 0.14–0.20 | 0.12 | ||||
| O (water) | 0.32 | Yes | ||||
| Amide C(O)NH | N (pyridine) | 0.44 | 0.34 | Yes | Yes | |
| O=C | 0.35 | 0.28 | Yes | Yes | ||
| N (pyrimidine) | 0.17 | 0.12–0.25 | Yes | Yes | ||
| N (piperidyl) | 0.11–0.16 | 0.10 | ||||
| O (water) | 0.27 | Yes | ||||
| Ammonium R3NH | N (pyridine) | 0.43 | ||||
| O=C | 0.37 | Yes | ||||
| N (pyrimidine) | 0.17 | |||||
| N (piperidyl) | 0.14 | |||||
| O (water) | 0.36 | Yes | Yes | |||
| Water H2O | N (pyridine) | 0.7 | Yes | Yes | ||
| O=C | 0.65 | Yes | ||||
| N (pyrimidine) | 0.39–0.49 | Yes | Yes | |||
| N (piperidyl) | 0.30 | Yes | Yes | |||
| O (water) | 0.63 | Yes | Yes |
1 Extended conformation; 2 folded conformation.
Figure 3Fragment of H-bonded motifs in crystals of (a) (HIma)(O3SCH3)·MeOH·H2O, CSD code XEJLUW [32] and (b) α-form of (HIma)(O3SCH3), CSD code XAVTOF [31]. H-bonds are dotted. Hydrogen atoms are omitted for clarity.
Figure 4H-bonded motifs in crystals of imatinib complexes with (a) tyrosine kinase (PDB code: 1T46 [34]) and (b) quinone oxidoreductase (PDB code: 3FW1 [29]). H-bonds are dotted. Hydrogen atoms are omitted.
Figure 5Molecular Voronoi polyhedron of imatinib in complex with the quinone oxidoreductase NQO2 (PDB code 3FW1 [29]) colored in accord with the nature of (a) inner, imatinib and (b) outer, receptor atoms. Color code: C-gray, H-green, N-blue, O-red. The π…π interactions in the region of pyrid-3-yl and the O…H interactions in the region of piperidine rings are additionally marked.
One-way analysis of variance (ANOVA) for π…π interactions.
| π…π (C…C only) | π…π (C…C and C…N) | |||||
|---|---|---|---|---|---|---|
| <0.0001 | <0.0001 | |||||
| Fexp | 176.8 | 440.5 | ||||
| Fcrit | 4.2 | 4.2 | ||||
| R2 | 0.95 | 0.98 | ||||
| Rmin | 0.94 | 0.97 | ||||
| Rmax | 1.00 | 0.99 | ||||
| ANOVA | SS | DF | MS | SS | DF | MS |
| Treatment (between columns) | 742.8 | 1 | 742.8 | 2552.5 | 1 | 2552.5 |
| Residual (within columns) | 105.0 | 25 | 4.2 | 144.9 | 25 | 5.8 |
| Total | 847.9 | 26 | 2697.3 | 26 | ||